Hubungan Komorbid dengan Mortalitas dan Lama Rawat Inap pada Pasien COVID-19 di Rumah Sakit UNS Surakarta


  • Gregorius Prama Suryaputra Fakultas Kedokteran UNS
  • Hendrastutik Apriningsih
  • Meirina Mulia Wardani



Background: Comorbid COVID-19 patients have worse outcomes or even death and have a longer length of stay than patients without comorbidities. The purpose of the study was to determine the relationship between comorbidities and mortality rates in COVID-19 patients at the UNS Surakarta Hospital.

Methods: An analytical observational study with a cross sectional approach, conducted in January-June 2021 at UNS Sukoharjo Hospital. The subjects of this study were patients, COVID-19 who were treated at UNS Sukoharjo Hospital. Sampling was carried out by purposive sampling and obtained a sample of 132 people consisting of 66 COVID-19 patients with comorbidities and 66 COVID-19 patients without comorbidities. Data collection using medical records was then analyzed statistically using the bivariate test with Chi Square (χ²) and Mann-Whitney test.

Results: Out of 132 samples, 26 samples have mortality as the outcome, with 20 patients having comorbid and 6 patients having no comorbid. Diabetes mellitus is the most frequent comorbid. To identify the effect of comorbid on mortality, chi-square test showed that the value is P=0.002. The mean value of Length of Stay in patients with comorbid is 10.18±5.94 days and without comorbid is 10.47±4.72 days. The results of the Mann Whitney test analysis obtained P value= 0.510.

Conclusion: There is a significant relationship between comorbidities and mortality rates and there is no relationship between comorbidities and length of stay in COVID-19 patients at UNS Hospital Surakarta.

Keywords: comorbidity, mortality rate, length of hospitalization.


komorbid, tingkat mortalitas, lama rawat inap


Azer SA (2020). COVID-19: Pathophysiology, Diagnosis, Complications and Investigational Therapeutics. New Microbes and New Infections, 37(M), pp.: 100738. doi: 10.1016/j.nmni.2020.100738.

Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, Firdaus I, Anwar S, et al. (2020). PEDOMAN TATALAKSANA COVID-19 Edisi 3. PDPI, PERKI, PAPDI, PERDATIN, IDAI.

Cai H (2020). Sex Difference and Smoking Predisposition in Patients with COVID-19. The Lancet Respiratory Medicine, 8(4), pp.: e20. doi: 10.1016/S2213-2600(20)30117-X.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC and Di Napoli R (2020). Features, Evaluation, and Treatment of Coronavirus. StatPearls, (Cdc), pp.: 19.

Chatterjee S, Khunti K and Davies MJ (2017). Type 2 Diabetes. The Lancet, 389(10085), pp.: 2239–2251. doi: 10.1016/S0140-6736(17)30058-2.

Chatterjee SK, Saha S and Munoz MNM (2020). Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19. Frontiers in Molecular Biosciences, 7(August), pp.: 1–11. doi: 10.3389/fmolb.2020.00196.

Chen TK, Knicely DH and Grams ME (2019). Chronic Kidney Disease Diagnosis and Management: A Review. JAMA, 322(13), pp.: 1294–1304. doi: 10.1001/jama.2019.14745.Chronic.

Essau CA (2020). Comorbidity of Addictive Problems: Assessment and Treatment Implications. Second Edi. Adolescent Addiction. Second Edi. Elsevier Inc. doi: 10.1016/b978-0-12-818626-8.00011-6.

Fraser S and Blakeman T (2016). Chronic Kidney Disease: Identification and Management in Primary Care. Pragmatic and Observational Research, Volume 7, pp.: 21–32. doi: 10.2147/por.s97310.

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H and Martín C (2020). Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 21(17), pp.: 1–34. doi: 10.3390/ijms21176275.

Goudouris ES (2020). Laboratory Diagnosis of COVID-19. Jornal de Pediatria, (January).

Goyal R and Jialal I (2021). Diabetes Mellitus, Type 2. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. doi: 10.1016/b978-3-437-42502-8.00154-6.

Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, Liu X-Q, Chen R-C, et al. (2020). Comorbidity and Its Impact on 1590 Patients with COVID-19 in China: A Nationwide Analysis. The European respiratory journal, 55(5), pp.: 2000547. doi: 10.1183/13993003.00547-2020.

Handayani D, Hadi DR, Isbaniah F, Burhan E and Agustin H (2020). Penyakit Virus Corona 2019. Jurnal Respirologi Indonesia, 40(2), pp.: 129.

Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M and Volpe Massimo M (2020). Age and Multimorbidity Predict Death among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension, 76(2). doi: 10.1161/HYPERTENSIONAHA.120.15324.

Iqbal AM and Jamal SF (2020). Essential Hypertension. StatPearls Publishing, 5, pp.: 193.

Johnson EL, Feldman H, Butts A, Billy CDR, Dugan J, Leal S, Rhinehart AS, Shubrook JH, et al. (2019). Standards of Medical Care in Diabetes—2019 Abridged for Primary Care Providers. Clinical Diabetes, 37(1), pp.: 11–34. doi: 10.2337/cd18-0105.

KDIGO (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3(1), pp.: 1–150. doi: 10.3182/20140824-6-za-1003.01333.

KPCPEN (2021). Peta Sebaran. Available at: (Accessed: March 17, 2021).

Kuswardhani RAT, Henrina J, Pranata R and Anthonius M (2020). Charlson Comorbidity Index and a Composite of Poor Outcomes in COVID-19 Patients : A Systematic Review and Meta-Analysis, (January).

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, et al. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine, 382(13), pp.: 1199–1207. doi: 10.1056/nejmoa2001316.

Li Xiaowei, Geng M, Peng Y, Meng L and Lu S (2020). Molecular Immune Pathogenesis and Diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 10(2), pp.: 102–108. doi: 10.1016/j.jpha.2020.03.001.

Li Xiaochen, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, et al. (2020). Risk Factors for Severity and Mortality in Adult COVID-19 Inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 146(1), pp.: 110–118. doi: 10.1016/j.jaci.2020.04.006.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, et al. (2020). Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China. The Lancet Oncology, 21(3), pp.: 335–337. doi: 10.1016/S1470-2045(20)30096-6.

Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, B. Pearson CA, Group CW, Jombart T, et al. (2020). COVID-19 Length of Hospital Stay: A Systematic Review and Data Synthesis. BMC Medicine, 18(1), pp.: 270. doi: 10.1186/s12916-020-01726-3.

Roffman CE, Buchanan J and Allison GT (2016). Charlson Comorbidities Index. Journal of Physiotherapy, 62(3), pp.: 171. doi: 10.1016/j.jphys.2016.05.008.

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, et al. (2020). Comorbidity and Its Impact on Patients with COVID-19. SN Comprehensive Clinical Medicine, 2(8), pp.: 1069–1076. doi: 10.1007/s42399-020-00363-4.

Sapra A and Bhandari P (2021). Diabetes Mellitus [Diabetes Mellitus]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

Shereen MA, Khan S, Kazmi A, Bashir N and Siddique R (2020). COVID-19 Infection: Origin, Transmission, and Characteristics of Human Coronaviruses. Journal of Advanced Research, 24, pp.: 91–98. doi: 10.1016/j.jare.2020.03.005.

Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnadi Y, Budiman, Ikhsan R, et al. (2019). Konsensus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia. Jakarta: PB Perkeni.

Sugihantono A, Burhan E, Samuedro E, Aryati, Rinawati W, Sitompul PA, Susilo A, Ginanjar E, et al. (2020). Pedoman Pencegahan Dan Pengendalian Coronavirus Disease (COVID-19) Revisi Ke-5. Kementeian Kesehatan RI.

Thiruvengadam G, Lakshmi M and Ramanujam R (2021). A Study of Factors Affecting the Length of Hospital Stay of COVID-19 Patients by Cox-Proportional Hazard Model in a South Indian Tertiary Care Hospital. Journal of Primary Care and Community Health, 12. doi: 10.1177/21501327211000231.

Vaidya SR and Aeddula NR (2020). Chronic Renal Failure. StatPearls, pp.: 1–591. doi: 10.3109/9780203640500.

Valderas JM, Starfield B and Sibbald B (2009). Defining Comorbidity: Implications for Understanding Health and Health Services. Annals Of Family Medicine, pp.: 357–363. doi: 10.1370/afm.983.Martin.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task F. Journal of the American Society of Hypertension. Elsevier. doi: 10.1016/j.jash.2018.06.010.

WHO (2021). WHO Coronavirus Disease (COVID-19) Data Table. Available at: (Accessed: March 17, 2021).

Wolff D, Nee S, Hickey NS and Marschollek M (2021). Risk Factors for Covid-19 Severity and Fatality: A Structured Literature Review. Infection, 49(1), pp.: 15–28. doi: 10.1007/s15010-020-01509-1.

Yuki K, Fujiogi M and Koutsogiannaki S (2020). COVID-19 Pathophysiology: A Review. Elsevier, (January).

Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L and Wang Y (2020). Comorbidities and the Risk of Severe or Fatal Outcomes Associated with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. International Journal of Infectious Diseases, 99, pp.: 47–56. doi: 10.1016/j.ijid.2020.07.029.